Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efalizumab plus methotrexate versus efalizumab alone in moderate to severe psoriasis
NL-OMON31349Phase 4Not yet recruiting
- Sponsor
- Radboud University Medical Center
- Start
- May 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of efalizumab and methotrexate in psoriasis (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Primary safety endpoint. Planned start May 2007; status: not yet recruiting.
02
Drugs
efalizumabmethotrexate
03
Conditions
psoriasis
Beyond the preview
Go deeper on NL-OMON31349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31349.